Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art

References

• Vogel A, Bathon M, Saborowski A. Advances in systemic therapy for the first-line treatment of unresectable HCC. Expert Rev Anticancer Ther. 2021;21:621–628. doi:10.1080/14737140.2021.1882855
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. IMbrave150: updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 2021;39:267. doi:10.1200/JCO.2021.39.3_suppl.267
   Web of Science ®Google Scholar
• Vogel A, Martinelli E, Cervantes A, et al. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical practice guidelines. Ann Oncol. 2021;32:801–805. doi:10.1016/j.annonc.2021.02.014
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol. 2022;40:379. doi:10.1200/JCO.2022.40.4_suppl.379
   Web of Science ®Google Scholar
• OncologyPRO. Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase; 2023. Available from: https://oncologypro.esmo.org/meeting-resources/esmo-congress/camrelizumab-c-plus-rivoceranib-r-vs.-sorafenib-s-as-first-line-therapy-for-unresectable-hepatocellular-carcinoma-uhcc-a-randomized-phase. Accessed February 2, 2023.
   Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Gül-Klein S, Kästner A, Haber PK, et al. Recurrence of hepatocellular carcinoma after liver transplantation is associated with episodes of acute rejections. J Hepatocell Carcinoma. 2021;8:133–143. doi:10.2147/JHC.S292010
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Dent R, et al. VP7-2021: KEYNOTE-522: phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC. Ann Oncol. 2021;32:1198–1200. doi:10.1016/j.annonc.2021.06.014
   Web of Science ®Google Scholar
• Topalian SL, Bhatia S, Amin A, et al. Neoadjuvant nivolumab for patients with resectable merkel cell carcinoma in the CheckMate 358 trial. In Journal of Clinical Oncology. American Society of Clinical Oncology; 2020:2476–2487.
   Google Scholar
• Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24:1655–1661. doi:10.1038/s41591-018-0198-0
   PubMed Web of Science ®Google Scholar
• Forde PM, Anagnostou V, Sun Z, et al. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the Phase 2 PrE0505 trial. Nat Med. 2021;27:1910–1920. doi:10.1038/s41591-021-01541-0
   PubMed Web of Science ®Google Scholar
• Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26:566–576. doi:10.1038/s41591-020-0805-8
   PubMed Web of Science ®Google Scholar
• Powles T, Kockx M, Rodriguez-Vida A, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med. 2019;25:1706–1714. doi:10.1038/s41591-019-0628-7
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7:1–28. doi:10.1038/s41572-020-00234-1
   PubMed Web of Science ®Google Scholar
• Zheng J, Chou JF, Gönen M, et al. Prediction of hepatocellular carcinoma recurrence beyond milan criteria after resection. In: Annals of Surgery. Lippincott Williams and Wilkins; 2017:693–701.
   Google Scholar
• Calderaro J, Rousseau B, Amaddeo G, et al. Programmed death ligand 1 expression in hepatocellular carcinoma: relationship With clinical and pathological features. Hepatology. 2016;64:2038–2046. doi:10.1002/hep.28710
   PubMed Web of Science ®Google Scholar
• Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378:1976–1986. doi:10.1056/NEJMoa1716078
   PubMed Web of Science ®Google Scholar
• Liu J, Blake SJ, Yong MCR, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6:1382–1399. doi:10.1158/2159-8290.CD-16-0577
   PubMed Web of Science ®Google Scholar
• Yao FY, Mehta N, Flemming J, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61:1968–1977. doi:10.1002/hep.27752
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Citterio D, Bhoori S, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol. 2020;21:947–956. doi:10.1016/S1470-2045(20)30224-2
   PubMed Web of Science ®Google Scholar
• Israelsen MB, Trošt K, Madsen BS, et al. Oral abstracts (Abstracts 1–288). Hepatology. 2019;70:1–187. doi:10.1002/hep.30940
   PubMedGoogle Scholar
• Hurkmans DP, Basak EA, Van Dijk T, et al. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. J Immunother Cancer. 2019;7. doi:10.1186/s40425-019-0669-y
   Web of Science ®Google Scholar
• Su C, Wang H, Liu Y, et al. Adverse effects of anti-PD-1/PD-L1 therapy in non-small cell lung cancer. Front Oncol. 2020;10. doi:10.3389/fonc.2020.554313
   Web of Science ®Google Scholar
• Ho WJ, Zhu Q, Durham J, et al. Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity. Nat Cancer. 2021;2:891–903. doi:10.1038/s43018-021-00234-4
   PubMedGoogle Scholar
• Zhu XD, Huang C, Shen YH, et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations. Liver Cancer. 2021;10:320–329. doi:10.1159/000514313
   PubMed Web of Science ®Google Scholar
• Zhang W, Hu B, Han J, et al. Surgery after conversion therapy with PD-1 inhibitors plus tyrosine kinase inhibitors are effective and safe for advanced hepatocellular carcinoma: a pilot study of ten patients. Front Oncol. 2021;11:215.
   Web of Science ®Google Scholar
• Xia Y, Tang W, Qian X, et al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. J Immunother Cancer. 2022;10:4656. doi:10.1136/jitc-2022-004656
   PubMed Web of Science ®Google Scholar
• D’Alessio A, Pai M, Spalding D, et al. Preliminary results from a phase Ib study of neoadjuvant ipilimumab plus nivolumab prior to liver resection for hepatocellular carcinoma: the PRIME-HCC trial. J Clin Oncol. 2022;40:4093. doi:10.1200/JCO.2022.40.16_suppl.4093
   Web of Science ®Google Scholar
• Kaseb AO, Hasanov E, Cao HST, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7:208–218. doi:10.1016/S2468-1253(21)00427-1
   PubMed Web of Science ®Google Scholar
• Marron TU, Fiel MI, Hamon P, et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7:219–229. doi:10.1016/S2468-1253(21)00385-X
   PubMed Web of Science ®Google Scholar
• Shi XL, Mancham S, Hansen BE, et al. Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction. J Hepatol. 2016;64:1274–1282. doi:10.1016/j.jhep.2016.02.034
   PubMed Web of Science ®Google Scholar
• Vogel A, Sterneck M, Vondran F, et al. The use of immuno-oncologic therapy in hepatocellular carcinoma in the context of liver transplantationAn interdisciplinary benefit/risk assessment. Z Gastroenterol. 2022;60:184–191. doi:10.1055/a-1649-8643
   PubMed Web of Science ®Google Scholar
• DeLeon TT, Salomao MA, Aqel BA, et al. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. J Gastrointest Oncol. 2018;9:1054–1062. doi:10.21037/jgo.2018.07.05
   PubMed Web of Science ®Google Scholar
• Gassmann D, Weiler S, Mertens JC, et al. Liver allograft failure after nivolumab treatment—A Case report with systematic literature research. Transplant Direct. 2018;4. doi:10.1097/TXD.0000000000000814
   PubMed Web of Science ®Google Scholar
• Tsung I, Worden FP, Fontana RJ. A pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma. Oncologist. 2021;26:133–138. doi:10.1002/onco.13539
   PubMed Web of Science ®Google Scholar
• Friend BD, Venick RS, McDiarmid SV, et al. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma. Pediatr Blood Cancer. 2017;64:189.
   Web of Science ®Google Scholar
• Zhuang L, Mou HB, Yu LF, et al. Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int. 2020;19:91–93. doi:10.1016/j.hbpd.2019.09.011
   PubMed Web of Science ®Google Scholar
• Tio M, Rai R, Ezeoke OM, et al. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. Eur J Cancer. 2018;104:137–144. doi:10.1016/j.ejca.2018.09.017
   PubMed Web of Science ®Google Scholar
• Delyon J, Zuber J, Dorent R, et al. Immune checkpoint inhibitors in transplantation—a case series and comprehensive review of current knowledge. Transplantation. 2021;105:67–78. doi:10.1097/TP.0000000000003292
   PubMed Web of Science ®Google Scholar
• Shi GM, Wang J, Huang XW, et al. Graft programmed death ligand 1 expression as a marker for transplant rejection following anti–programmed death 1 immunotherapy for recurrent liver tumors. Liver Transplant. 2021;27:444–449. doi:10.1002/lt.25887
   PubMed Web of Science ®Google Scholar
• Tabrizian P, Florman SS, Schwartz ME. PD‐1 inhibitor as bridge therapy to liver transplantation? Am J Transplant. 2021;21:1979–1980. doi:10.1111/ajt.16448
   PubMed Web of Science ®Google Scholar
• Schwacha-Eipper B, Minciuna I, Banz V, Dufour JF. Immunotherapy as a downstaging therapy for liver transplantation. Hepatology. 2020;72:1488–1490. doi:10.1002/hep.31234
   PubMed Web of Science ®Google Scholar
• Nordness MF, Hamel S, Godfrey CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient? Am J Transplant. 2020;20:879–883.
   PubMed Web of Science ®Google Scholar
• Schnickel GT, Fabbri K, Hosseini M, et al. Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab. Am J Transplant. 2022;22:1699–1704. doi:10.1111/ajt.16965
   PubMed Web of Science ®Google Scholar
• Lizaola-Mayo BC, Mathur AK, Borad MJ, et al. Immunotherapy as a downstaging tool for liver transplantation in hepatocellular carcinoma. Am J Gastroenterol. 2021;116:2478–2480. doi:10.14309/ajg.0000000000001391
   PubMed Web of Science ®Google Scholar
• Liu J, O’Donnell JS, Yan J, et al. Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. Oncoimmunology. 2019;8:e1581530. doi:10.1080/2162402X.2019.1581530
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–3175. doi:10.1200/JCO.2009.26.7609
   PubMed Web of Science ®Google Scholar
• Centanni M, Moes DJ, Trocóniz IF, Ciccolini J, van Hasselt JGC. Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet. 2019;58:835–857. doi:10.1007/s40262-019-00748-2
   PubMed Web of Science ®Google Scholar
• Pfister D, Núñez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592:450–456. doi:10.1038/s41586-021-03362-0
   PubMed Web of Science ®Google Scholar
• Dudek M, Pfister D, Donakonda S, et al. Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH. Nature. 2021;592:444–449. doi:10.1038/s41586-021-03233-8
   PubMed Web of Science ®Google Scholar